DELBIOS Pharmaceuticals - Drug development of advanced nanomedicine solutions, is the second spin-off created by the Nanomol-bio group. Delbios Pharmaceuticals focuses on the research, development, production, and marketing of technological solutions in the field of nanomedicine for the treatment of rare diseases.
This spin-off, created in 2024 represents a key step towards the transfer and valorisation of the European project Nano4Rare results.
NANOMOL TECHNOLOGIES is the first spin-off created from our group. It offers R&D services and advanced technologies to generate new nanomedicines and solutions for drug delivery that improve drug efficacy, selectivity, stability, and toxicity.
It is a privately held company created in 2010 and located at the Autonomous University of Barcelona Research Park in Mòdul de Recerca B (Building IBB). It was created to exploit the business potential of proprietary knowledge and technologies in micro- and nanostructuring of active ingredients.
